step toward addressing them. Methodology As a part of the initiative to adapt the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non–Small Cell Lung Cancer 11 to the MENA region, a lung cancer guidelines committee was
Search Results
Abdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, Rabab Mohamed Gaafar, Fady B. Geara, Mansur Javaid, Jamal Khader, Kian Khodadad, Walid Omar, Ahmed Saadeddin, Hassan Al Sabe, Mohammad Behgam Shadmehr, Amgad El Sherif, Najam Uddin, Mohammad Jahanzeb, and David Ettinger
William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Vishala T. Neppalli, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Mary A. Dwyer, and Hema Sundar
be able to: Integrate into professional practice the updates to the NCCN Guidelines for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Chronic
Mary B. Daly, Robert Pilarski, Michael Berry, Saundra S. Buys, Meagan Farmer, Susan Friedman, Judy E. Garber, Noah D. Kauff, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Shaveta Vinayak, Nicoleta C. Voian, Jeffrey N. Weitzel, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, and Susan Darlow
to NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian
David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr., Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, Giuseppe Sanguineti, David E. Schuller, Jatin P. Shah, Sharon Spencer, Andy Trotti III, Randal S. Weber, Gregory T. Wolf, and Frank Worden
. Overview This shortened version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck (H&N) Cancers addresses tumors arising in the oral cavity, oropharynx, hypopharynx, and nasopharynx (see Figure 1 ). 1 Other types
Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee, and Joseph E. Ippolito
Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection recommend that mpMRI may be considered in men with indications for biopsy (eg, elevated PSA) to reduce the number of men undergoing biopsy that will in turn reduce the
Wells A. Messersmith
In the past year, the most significant changes to the management of metastatic disease in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colorectal Cancer (CRC) were related to biomarkers and subsets of the disease
Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar
2 decades. 2 As a result, patients with NHL may also have significant comorbid conditions, which complicate treatment options. NOTE: This manuscript highlights only a portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
Omar Shamieh and Abdul-Rahman Jazieh
A n initiative was launched to adapt several of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to the Middle East and North Africa (MENA) region. Palliative care was one area of cancer treatment selected because of its high
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
pressing need exists for the MENA region to develop guidelines for breast cancer management. This explains the interest in participating in NCCN Guidelines development to improve the quality of oncology practice in the region. Material and Methods The
Ali Bazarbachi, Hamdy A. Azim, Hussain Alizadeh, Mahmoud Aljurf, Ibrahim Barista, Naeem A. Chaudhri, Zahira Fahed, Omar A. Fahmy, Ardeshir Ghavamzadeh, Mohamed H. Khalaf, Sami Khatib, Aghiad Kutoubi, Semra Paydas, Hanadi Rafii Elayoubi, Ghazi Zaatari, Hamdy M. Zawam, and Andrew D. Zelenetz
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Non-Hodgkin's Lymphoma and the 2008 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hodgkin Lymphoma (to view the most recent version of these
